Another potential vaccine against the virus that causes Covid-19 hit the clinic in the U.S. Tuesday as the companies sponsoring its development gave the first Stateside shots in their clinical trial.
New York-based Pfizer and Mainz, Germany-based BioNTech said they had dosed the first American participants in the Phase I/II trial of BNT162, as part of a global clinical development program. The participants were taking part at the medical schools of New York University and the University of Maryland, in Baltimore. The first cohort of participants in Germany completed dosing last week, Pfizer and BioNTech said.
Image: https://medcitynews.com - The entrance to a Pfizer office in Cambridge, Massachusetts
